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1334Objective: The present study sought to determine the long-term quality of life (QOL) of children who required
long-term ventricular assist device (VAD) support as a bridge to transplantation (BTT) compared with children
who underwent heart transplantation without VAD support. Currently, 20% of children undergoing heart
transplantation have required a VAD as a BTT. Few data have been published assessing how children requiring
a VAD as a BTT will fair in terms of their long-term QOL.
Methods: The present study used a cross-sectional design, using the Core and Cardiac modules of the Pediatric
Quality of Life Inventory survey. In a secondary analysis, the factors associated with worse QOL outcomes
among the VAD patients were also investigated.
Results: At follow-up (median, 4.2 years), between the 21 children who required a VAD as a BTT and 42 who
went straight to transplantation, no significant differences were found in the QOL as measured using the
Psychosocial Health Summary Score, Physical Health Summary Score, or Total Score in the survey’s Core
Module, nor were any differences found in the outcomes assessed using the survey’s Cardiac Module. Of the
patients who required a VAD, only the presence of a neurologic complication was associated with worse
QOL, which was demonstrated by decreased Physical Health Summary and Cardiac Communication scores.
Conclusions: Over the long term, surviving children who required a long-term VAD as a BTT experience a
similar QOL as those who went straight to transplantation. (J Thorac Cardiovasc Surg 2014;147:1334-43)In recent years, the number of children supported by a
ventricular assist device (VAD) has increased considerably,
with up to 20% of children undergoing heart transplanta-
tion requiring a bridge with a VAD,1 a dramatic increase
from the early 1990s.2 Pediatric VAD use is likely to
increase further, given the recent US Food and Drug
Administration approval of the Berlin Heart EXCOR
Pediatric VAD (Berlin Heart AG, Berlin, Germany).3
VADs have been shown to improve survival to transplanta-
tion compared with extracorporeal membrane oxygenation
(ECMO).4,5 VAD use as a bridge to transplantation (BTT)
has had equal or better rates of post-transplantation survival
compared to medical therapy alone as a BTT,6-13 although
the outcome data have been limited. With the efficacy of
adult and pediatric VAD use established, it is appropriate
to assess the long-term outcomes beyond survival alone.e Section of Pediatric Cardiologya and Section of Congenital Heart Surgery,b
Children’s Hospital, Baylor College of Medicine, Houston, Tex.
res: Texas Children’s Hospital is contracted to be the Berlin Heart Reference
raining Center in the United States. Dr Heinle receives no personal
ensation for his involvement with Berlin Heart. All other authors have
g to disclose with regard to commercial support.
d for publication July 10, 2013; revisions received Sept 22, 2013; accepted for
ation Oct 6, 2013; available ahead of print Dec 16, 2013.
for reprints: David S. Ezon, MD, Section of Pediatric Cardiology, Texas
ren’s Hospital, Baylor College of Medicine, 6621 Fannin St, MC-19345-C,
ton, TX 77030 (E-mail: DSEzon@texaschildrens.org).
23/$36.00
ht  2014 by The American Association for Thoracic Surgery
.doi.org/10.1016/j.jtcvs.2013.10.007
The Journal of Thoracic and Cardiovascular SurPediatric VAD use is associated with a high rate of
infection, stroke, and bleeding,4 all of which can cause
significant morbidity with respect to the neurologic and
quality of life (QOL) outcomes. Our aim was to assess the
QOL of children who required a long-term VAD as a
BTT compared with those patients who went straight to
transplantation (STT).METHODS
We used a cross-sectional study design to evaluate QOL outcomes in
pediatric survivors after heart transplantation, comparing those patients
supported with a VAD as a BTT and patients never supported by a VAD.
The patients selected for inclusion had undergone heart transplantation
from January 2005 to August 2011 at our institution, were18 years old at
transplantation, were 1 year post-transplantation, and were alive during
the study period. Patients were excluded from the study if they had
undergone previous transplantation, had previously been weaned from a
VAD, or had undergone multiorgan transplantation. The BTT group was
composed of those patients who had required long-term VAD support,
defined as 14 days. This minimum duration of support was used because
it has been our institution’s practice to consider long-term use of VADs for
patients expected to require support for 14 days.
We conducted a secondary analysis limited to those patients supported
by a VAD as a BTT to evaluate which patient and device characteristics
might be associated with a lower QOL score.
With the approval of our institutional review board, the parents of each
patient who had undergone heart transplantation were interviewed by
telephone. After obtaining consent, they were asked to complete the
Pediatric Quality of Life Inventory (PedsQL) Core Module version 4.0
and the PedsQL Cardiac Module version 3.0 by telephone.
The Core Module of the PedsQL survey consists of 21 to 23 questions
that assess the patient’s level of physical, emotional, social, and schoolgery c April 2014
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TPN ¼ total parenteral nutrition
VAD ¼ ventricular assist device
Ezon et al Cardiothoracic Transplantationfunctioning. The participants are asked to rate the patient’s difficulty with
various activities or symptoms using a 5-point Likert scale. The score is
then translated to a point system from 0 to 100, where 0 indicatesTABLE 1. Group characteristics
Characteristic Total (n ¼ 6
Gender
Male 36 (57)
Female 27 (43)
Race
Asian 2 (3)
Black 15 (24)
Hispanic 22 (35)
White 24 (38)
Age at follow-up (y)
2-4 12 (19)
5-12 28 (44)
>13 23 (37)
Highest parent reported education
Higher than HS degree 44 (70)
HS degree 11 (17)
Less than HS degree 8 (13)
Heart failure etiology
Acquired 45 (71)
Congenital 18 (29)
Total previous CPB frequency
0 41 (65)
1-2 16 (25)
>2 6 (10)
Intubated 20 (32)
Hemodialysis use 2 (3)
TPN use 18 (29)
Parent report of current chronic health condition 12 (19)
Parent report of overnight hospital visit in previous year 28 (44)
Parent report of ED/urgent care visit in previous year 32 (51)
Age at follow-up (y) 9.04 (5.6-17
Age at transplantation (y) 5.13 (1.1-12
Interval since transplantation (y) 4.21 (2.9-5.8
Ischemic time* (min) 263 (206-31
Poverty level by census block 12.8 (5.3-22
Data presented as n (%) or median (interquartile range [25th-75th]). BTT, Bridge to trans
bypass; TPN, total parenteral nutrition; ED, emergency department. *Ischemic time availa
The Journal of Thoracic and Carsignificant impairment in function and 100 indicates no impairment. The
scores are then aggregated into a Psychosocial Health Summary Score,
consisting of the weighted average of the emotional, social, and school
functioning scores, a Physical Health Summary Score, consisting of the
physical functioning score, and a total score. The PedsQL includes
5 different surveys according to the patient’s age group: 2 to 4, 5 to 7, 8
to 12, 13 to 18, and 18 to 25 years old. The surveys are similar, with
only slight modifications in wording related to patient age (eg, use of the
word ‘‘teen’’ instead of ‘‘child’’) and excluding 2 nonapplicable questions
for the 2- to 4-year-old group.
The Cardiac Module of the PedsQL survey assesses 6 dimensions of
QOL: symptoms related to cardiac disease, problems related to heart
medication, problems related to the patient’s perceived physical
appearance, treatment anxiety, cognitive problems, and communication
problems. As with the Core Module, the Cardiac Module has versions
for each age group. Because the Cardiac Module does not have a version
for patients>18 years old, the survey for patients aged 13 to 18 years
was used, substituting the term ‘‘young adult’’ for ‘‘teen.’’
The PedsQL survey was administered over the course of 1 month,
and the first available parent or guardian was interviewed. The PedsQL
Core and Cardiac Modules have been previously validated for both3) BTT (n ¼ 21) STT (n ¼ 42) P value
12 (57) 24 (57) 1.00
9 (43) 18 (43)
0 (0) 2 (5) .11
7 (33) 8 (19)
10 (48) 12 (29)
4 (19) 20 (48)
7 (33) 5 (12) .54
5 (24) 23 (55)
9 (43) 14 (33)
12 (57) 32 (76) .11
5 (24) 6 (14)
4 (19) 4 (6)
18 (86) 27 (64) .08
3 (14) 15 (36)
17 (81) 24 (57) .03
4 (19) 12 (29)
0 (0) 6 (14)
12 (57) 8 (19) <.01
2 (10) 0 (0) .11
12 (57) 6 (14) <.01
4 (19) 8 (19) 1.00
10 (48) 18 (43) .72
12 (57) 20 (48) .48
.3) 7.38 (4.3, 18.0) 9.42 (6.6-15.5) .37
.6) 4.28 (1.0-13.5) 5.3 (1.22-10.3) .76
) 3.33 (2.8-3.8) 4.81 (3.4-6.4) <.01
3) 264 (211-297) 260 (205-327) .96
.4) 12.8 (6.1-29.7) 12.8 (4.7-21.6) .44
plantation; STT, straight to transplantation; HS, high school; CPB, cardiopulmonary
ble for only 55 patients.
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TABLE 2. PedsQL Cardiac and Core Module scores
PedsQL Section
Total BTT STT
P valueMedian IQR Median IQR Median IQR
Core Module
Psychosocial Health Summary 83.3 69.2-90.8 81.7 70.0-90.0 84.2 68.3-91.7 .66
Physical Health Summary 87.5 71.9-100 90.6 75.0-96.9 84.4 68.8-100 .80
Total score 82.6 71.0-91.3 81.94 70.7-92.9 82.6 71.7-91.3 .53
Cardiac Module
Heart problems and treatment 89.3 85.4-96.4 92.9 85.7-100 89.3 82.1-96.4 .28
Treatment II 100 90.0-100 95.8 83.0-100 100 90-100 .33
Perceived physical appearance 100 83.3-100 100 83.3-100 100 83.3-100 .54
Treatment anxiety 100 75.0-100 87.5 62.5-100 100 81.3-100 .43
Cognitive problems 80.0 50.0-95 80 50.0-95.0 77.5 55.0-95.0 .58
Communication 100 75.0-100 100 66.7-100 100 83.3-100 .28
PedsQL, Pediatric Quality of Life Inventory; BTT, bridge to transplantation; STT, straight to transplantation; IQR, interquartile range (25th-75th percentiles).
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1 of 2 trained instructors, who followed the PedsQL script exactly and
audited each other’s interviews to ensure consistency was maintained.
For Spanish-speaking parents, an interviewer fluent in Spanish conducted
the interview.
Although the PedsQL survey includes both a parent survey and a
self-survey completed by the patient, the present study used only the
parent survey to ensure interview feasibility by telephone and to maintain
consistency among the patients of each age group. The parent survey has
been validated independently of the self-survey.16
The potential confounders of the relationship between pretransplanta-
tion VAD support and QOL were considered a priori and were collected
from the electronic medical record systems and available billing data.
Data were collected for each patient’s demographic information, age at
transplantation, age at the PedsQL survey, heart failure etiology, medical
history, time since transplantation, and current health condition as
perceived by the parents, including recent illnesses, hospital admissions,
or presentation to the emergency room.
As a proxy for socioeconomic status, the percentage of persons living in
poverty in the patient’s census block group, a previously validatedmeasure,
was collected from the 2010 United States Census data.18,19 For 3 patients,FIGURE 1. Median Pediatric Quality of Life Inventory scores and 25th to
75th interquartile range (IQR). The scores were similar for the bridge to
transplantation (BTT) and straight to transplantation (STT) groups in each
of the core and cardiac categories.
1336 The Journal of Thoracic and Cardiovascular Surthe residential address was unknown, so the poverty level for the ZIP code
of the patient’s post office box was used.
For the secondary analysis evaluating the variables associated with
lower PedsQL scores within the VAD group, the Interagency Registry for
Mechanically Assisted Circulatory Support (INTERMACS) score at
VAD implantation, VAD duration, VAD type, and VAD complications
were collected. The data collected to assess whether a patient required
mechanical ventilation, hemodialysis, or total parenteral nutrition (TPN)
at VAD implantation were taken from billing data for the day before
VAD implantation because applicable medical records were not available
for all patients. For comparison, similar data were collected for STT
patients from the day before transplantation. A patient was considered to
have had a neurologic complication if either a new neuroradiologic finding
appeared while the patient was maintained on the VAD or new neurologic
symptoms developed during VAD support (eg, seizure).
Descriptive data were reported using proportions, medians, and 25th to
75th percentile interquartile range. A comparison of the characteristics
between the BTTand STT groups was performed using the c2, c2 for trend,
and Fisher exact tests for categorical variables and the Mann-WhitneyU or
Kruskal-Wallis test for continuous variables, as appropriate. A comparison
of the QOL scores between the BTT and STT groups and among the
characteristics within the VAD subanalysis were performed using the
Mann-Whitney U test and Spearman’s rank correlation. The 5- to 7-year-
old group was combined with the 8- to 12-year-old group for the individual
analysis by age group, because the latter group contained only 1 BTT
patient.
RESULTS
From January 2005 to August 2011, 101 patients under-
went heart transplantation at Texas Children’s Hospital.
Of these, 34 required a VAD before transplantation. Of
the 101 patients, 26 were excluded from the study (8 BTT
and 18 STT patients) because they did not meet the
inclusion criteria, and 12 (5 BTT and 7 STT patients)
were excluded because they were deceased at the time of
the study. The remaining 63 patients (21 BTT and 42
STT) were included in the study. The parents or guardians
of all included patients were successfully contacted. One
parent, whose child was in the STT group, declined to
complete the survey, yielding a 98% completion rate. Of
the surveyed BTT patients, 13 had been supported with a
Berlin EXCOR (Berlin Heart AG), 6 with a HeartMate IIgery c April 2014
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(Maquet Cardiovascular, Wayne, NJ), and 1 with a
Micromed VAD (MicroMed Technology, Inc, Houston,
Tex). The median duration of VAD support was 80 days
(range, 16-262).
Four patients surveyed were supported by ECMO at
1 point in their course, 2 of whom were bridged to
transplantation with a VAD. Only 1 patient required
ECMO for>5 days, and he was not in the VAD group.
The median age at transplantation was 5.1 years (range,
2 months to 18 years), and the median age at follow-up
was 9 years, with no significant differences in age between
the BTT and STT groups (Table 1). The BTT patients
had undergone heart transplantation more recently, with a
median interval since transplantation of 3.3 years (inter-
quartile range, 2.7-3.8) versus 4.8 years (interquartile range,
3.4-6.4, P< .01) for the STT patients. The 2 groups had
similar characteristics of gender, race, socioeconomic
status, and parent education. The BTT patients were more
likely to have been supported with TPN and ventilator
support on the day before VAD placement. No significant
difference was found in the incidence of recent illness,
presentation to the hospital, or perceived chronic health
condition, as reported by the parents, factors that might
have influenced the parental response to the survey.
The median Psychosocial Health Summary Score,
Physical Health Summary Score, and total score for the
PedsQL Core Module were similar for the BTT and STT
groups (Table 2 and Figure 1). The median total score for
the Core Module was 82.6, similar to that of healthy
subjects, previously demonstrated to have a mean total
score of 82.3.17 The median scores of the BTT and STT
patients were also similar to the mean scores for patients
with moderate cardiovascular disease, defined as those
patients who had undergone surgically correction or no
longer required therapy, who were previously shown to
have a mean total score of 84.6.20 Median data from either
study were unavailable for comparison. The scores were
also compared by each age-stratified subgroup for the 6
dimensions of the PedsQL Cardiac Module. No difference
was found in the outcomes for BTT patients compared
with the STT patients (Appendix Table 1).
The secondary analysis of scores for patients who
required a VAD as a BTT for any VAD specific factors
that might have affected the QOL outcome demonstrated
significant findings (Appendix Table 2). The QOL scores
did not differ by VAD duration, age at transplantation, or
INTERMACS score at VAD placement (Table 3). Of the
VAD patients, 62% were supported by a pulsatile VAD,
and the scores were not different between those with
pulsatile versus continuous VAD support. Additional
indicators of the patient’s degree of illness at VAD
placement, including ventilatory support, hemodialysis
use, and TPN use, were not associated with a significantThe Journal of Thoracic and Cardifference in outcome. Also, the patients faired similarly
regardless of whether the etiology of heart failure was
acquired or congenital heart disease and regardless of the
number of previous cardiopulmonary bypass runs they
had experienced. No differences were found in the QOL
scores among the race categories or by socioeconomic
status. Complications, including VAD-related infection,
reoperation or pump change, and neurologic complications,
were also assessed. Only the presence of a neurologic
complication (n ¼ 5) was associated with a lower QOL
score, with a statistically significant difference in the
patient’s Physical Health Summary score (50 vs 94) and
Cardiac Communication score (67 vs 100).
In the BTT patients, the interval since transplantation had
a moderate positive correlation with the QOL score in the
Cardiac Communication dimension that was statistically
significant (correlation coefficient, 0.52; P ¼ .01). Patient
age at follow-up also demonstrated a moderate positive cor-
relation with the Cardiac Communication score in the BTT
patients.
DISCUSSION
Recent evidence has shown that a VAD can effectively
support a pediatric patient to heart transplantation.21
However, pediatric VAD support has had a significant
complication rate, especially for younger children requiring
extracorporeal devices, with the potential to affect the
long-term QOL of patients. These complications have
included bleeding (42%-50%), infection (50%-63%),
and stroke (29%).4 The present study is the largest to date
to assess the long-term QOL outcomes of pediatric patients
who required VAD support as a BTT compared with
patients who went STT.
One recent study used the PedsQL Core Module to
determine the QOL outcomes in patients using mechanical
circulatory support. However, these had focused mainly on
patients bridged with ECMO, with, at most, 11 patients
sustained by a VAD. The study found similar QOL
outcomes for patients requiring mechanical circulatory
support compared to the STT group.22
In a recent study by Uzark and colleagues23 of the
long-term QOL outcomes of 174 pediatric patients
who had undergone heart transplantation, the patients
demonstrated significantly lower psychosocial and physical
functioning scores compared with the healthy norms and
patients who had undergone curative heart surgery. VAD
use was not evaluated in their study.23
Our study did not demonstrate any statistically significant
difference between the BTT and STT patients for the Core
or Cardiac Module outcomes, either in total or for each age
category. Both groups also scored similarly to published
normative values for the PedsQL survey. More than 33%
of heart transplantation patients in the study by Uzark and
colleagues23 had impaired psychosocial functioning scores,diovascular Surgery c Volume 147, Number 4 1337
TABLE 3. Factors affecting outcome of patients bridged to transplantation with VAD
PedsQL section
Neurologic complication VAD type Gender
Yes (n ¼ 5) No (n ¼ 16) P value Pulsatile (n ¼ 13) Continuous (n ¼ 8) P value Male (n ¼ 12)
Core
Psychosocial 61.7 (61.5-84.6) 82.5 (71.7-90.8) .24 84.6 (65.4-92.3) 76.7 (70-83.3) .34 74.17 (62.6-86.7)
Physical 50 (34.4-78.1) 93.8 (76.6-100) .01 90.6 (62.5-100) 89.1 (76.6-95.3) .86 92.18 (68.7-100)
Total 68.1 (51.2-71.2) 85.32 (79.4-93.2) .09 85.9 (67.9-93.5) 80.4 (74.5-85.3) .64 82.61 (66.1-89.7)
Cardiac
Heart problems and
treatment
92.86 (78.6-92.9) 91.1 (85.7-100) .49 92.9 (89.3-100) 85.7 (82.1-96.4) .30 98.21 (87.5-100)
Treatment II 91.7 (90.0-100) 100 (80.0-100) .90 100 (83.3-100) 90 (80-100) .41 95.83 (81.7-100)
Perceived physical
appearance
100 (83.3-100) 100 (87.5-100) .90 100 (91.7-100) 100 (62.5-100) .59 100 (91.7-100)
Treatment anxiety 100 (75.0-100) 87.5 (59.4-100) .72 87.5 (62.5-100) 100 (68.8-100) .37 100 (71.9-100)
Cognitive problems 50 (30.0-91.7) 80 (50-97.5) .40 50 (50-83.3) 90 (62.5-100) .21 55 (42.5-92.5)
Communication 66.67 (0-83.3) 100 (83.3-100) .02 83.3 (25.0-100) 100 (95.8-100) .14 100 (66.7-100)
Data presented as median (IQR [25th-75th percentile]) or correlation coefficient. VAD, Ventricular assist device; PedsQL, Pediatric Quality of Life Inventory; INTERMACS,
Interagency Registry for Mechanically Assisted Circulatory Support.
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population mean. Our patients faired much better, with
only 14% of STT patients and 19% of BTT patients scoring
low.
Our outcomes are more consistent with the results
of another study by Uzark and colleagues,20 which demon-
strated that nearly 16% of patients with cardiovascular
disease of any sort had impaired psychosocial functioning
scores. The scores were inversely proportional to the degree
of cardiovascular illness. The patients in our study had a
median total score similar to the mean total score of the
children in the study by Uzark and colleagues20 who had
had moderate cardiovascular disease, defined as those
who had undergone curative surgery or no longer required
medications.
We found few statistically significant risk factors
among the patients who required a VAD. Neurologic
complications, including radiologically evident stroke and
seizures, were associated with poorer Physical Health
Summary scores on the Core Module and lower Communi-
cation scores on the Cardiac Module. This might reflect
the long-term nature of the neurologic injury sustained
by the patient and should raise concerns about the patient’s
future neurodevelopment. Closer long-term follow-up
might be indicated for these patients to assess and treat
any developmental problems that occur.
Although the recent Berlin Heart study by Fraser and
colleagues4 reported that the complication rate increased
with VAD duration, the present study did not establish
any significant correlation between VAD duration and
QOL outcome. The difference might have been because
the study by Fraser and colleagues4 considered all patients
with VAD use, including nonsurvivors, and our study the
assessed outcomes only for patients well enough to both
survive to transplantation and be alive at the time of the
present study.1338 The Journal of Thoracic and Cardiovascular SurAlthough the severity of illness at transplantation has
been shown to increase the risk of graft rejection in the
long term in pediatric patients,24 the INTERMACS score,
need for ventilatory support, TPN, or hemodialysis at
VAD placement did not correlate with the QOL outcome.
Also, the heart failure etiology did not affect the outcome.
It might be that maintenance of adequate cardiac output
with a VAD while awaiting transplantation is associated
with improved post-transplantation QOL in patients who
are particularly ill, or it might be a reflection of selection
bias.
Among the BTT patients, both age at follow-up and the
interval since transplantation had a moderate positive
correlation with the Cardiac Communication score. The
questions constituting the PedsQL Cardiac Communication
assessment have focused on the patients’ ability to discuss
their medical condition with others, an ability that likely
increases with age, explaining why a longer interval since
transplantation demonstrated improved outcomes.
Altogether, our results have shown that patients who
require a VAD to maintain circulatory support as a BTT
are likely to have QOL outcomes, as perceived by their
parents, comparable to those who went STT. Furthermore,
the indicators of the child’s degree of illness at VAD
implantation, measures of the child’s socioeconomic status,
and VAD type does not appear to affect the QOL outcomes.
Only the occurrence of neurologic complications was
shown to have some potential effect on the long-term
outcomes.
One limitation of the present study was its small sample
size, which might have limited the power to detect more
subtle differences between the 2 groups. Another limitation
was the use of only the parent survey. This was done both to
maximize the response rate, given the easier access to
patients by telephone, and to have comparable results across
all age groups. Previous studies have shown the correlationgery c April 2014
Gender VAD duration Age at transplantation INTERMACS score at VAD placement
Female (n ¼ 9) P value Correlation coefficient P value Correlation coefficient P value Correlation coefficient P value
84.62 (81.7-92.3) .07 0.13 .56 0.11 .62 0.32 .17
87.5 (75.0-93.7) .60 0.07 .75 0.25 .26 0.05 .83
81.94 (78.3-92.9) .38 0.06 .81 0.08 .71 0.25 .30
85.71 (85.7-92.9) .07 0.02 .93 0.06 .79 0.64 .79
100 (83.3-100) .86 0.12 .59 0.02 .92 0.32 .18
100 (83.33-100) .46 0.005 .98 0.06 .81 0.23 .35
75 (56.25-100) .34 0.05 .82 0.41 .06 0.02 .93
80 (50-95) .46 0.185 .42 0.32 .16 0.01 .97
100 (33.3-100) .86 0.351 .12 0.36 .11 0.18 .46
TABLE 3. Continued
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believe the inclusion of patient responses would not have
resulted in significantly different results.17,22,23 Although
the results demonstrated similar parental perceived QOL
between the BTT and STT groups, only limited
conclusions could be drawn about the patient’s perceived
QOL. Finally, our study was an assessment of the QOL in
surviving patients. Thus, the results could reflect survivor
bias, because the QOL could not be measured in the most
severely ill patients who had died.
CONCLUSIONS
The results of the present study have helped to establish
that the QOL is similar between VAD-supported patients
and those who went STT. Additional studies are required
to assess the long-term QOL of VAD patients as the
technology evolves. Incorporating QOL scores and
preventative strategies into patient care may be beneficial.
The present study provides additional information to
clinicians, patients, and their families during the
decision-making process for VAD use.
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APPENDIX TABLE 1. PedsQL Cardiac and Core Module scores stratified by age category
PedsQL section Age category (y)
Total BTT STT
P valueMedian IQR Median IQR Median IQR
Core
Psychosocial Health
Summary
Total 83.3 69.2-90.8 81.7 70.0-90.0 84.2 68.3-91.7 .66
2-4 84.8 69.2-93.3 84.8 64.4-88.6 85 76.9-94.2
5-12 81.7 66.7-90 81.7 78.3-90 81.67 66.7-88.3
>13 83.3 75-90.8 80 70-83.3 86.67 78.3-91.7
Physical Health Summary Total 87.5 71.9-100 90.6 75-96.9 84.38 68.7-100 .80
2-4 76.6 56.2-92.2 75 56.2-84.4 100 75-100
5-12 82.8 56.2-100 100 93.7-100 75 56.2-100
>13 90.6 78.1-96.9 90.6 78.1-96.9 92.19 78.1-96.8
Total score Total 82.6 71-91.3 81.9 70.6-92.9 82.61 71.7-91.3 .53
2-4 80.7 66.1-94.6 71.4 66.1-87.4 80.95 80.5-96.4
5-12 83.1 62-89.7 88.0 85.9-93.5 80.43 62-87.5
>13 84.8 78.3-90.8 80.4 78.3-85.9 88.59 78.3-91.3
Cardiac
Heart problems and
treatment
Total 89.3 85.4-96.4 92.9 85.7-100 89.28 82.1-96.4 .28
2-4 92.9 87.5-94.6 92.9 87.5-94.6 92.86 89.3-92.9
5-12 89.3 83.9-96.4 96.4 89.3-100 85.71 83.9-92.9
>13 89.3 80.4-98.2 85.7 85.7-100 91.07 78.6-96.4
Treatment II Total 100 90-100 95.8 83-100 100 90-100 .33
2-4 95.8 83.3-100 83.3 79.2-100 100 91.7-100
5-12 100 91.7-100 100 100-100 100 90.8-100
>13 95 87.5-100 90 80-100 95 90-100
Perceived physical
appearance
Total 100 83.3-100 100 83.3-100 100 83.3-100 .54
2-4 100 100-100 100 95.8-100 100 100-100
5-12 100 83.3-100 100 83.3-100 100 87.5-100
>13 83.3 66.7-100 100 83.3-100 83.33 66.7-100
Treatment anxiety Total 100 75-100 87.5 62.5-100 100 81.2-100 .43
2-4 81.2 65.6-100 75 31.2-87 93.75 87.5-100
5-12 93.7 78.1-100 87.5 87.5-100 93.75 78.1-100
>13 100 84.4-100 100 81.2-100 100 87.5-100
Cognitive problems Total 80 50-95 80 50-95 77.5 55-95 .58
2-4 70.8 50-95.8 50 50-87.5 75 66.7-100
5-12 65 50-92.5 50 40-60 75 50-95
>13 85 70-97.5 95 80-100 80 100-100
Communication Total 100 75-100 100 66.7-100 100 83.3-100 .28
2-4 45.8 0-100 25 0-91 66.67 0-100
5-12 100 66.7-100 100 66.7-100 100 75-100
>13 100 100-100 100 100-100 100 100-100
PedsQL, Pediatric Quality of Life Inventory; BTT, bridge to transplantation; STT, straight to transplantation; IQR, interquartile range (25th-75th percentiles).
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APPENDIX TABLE 2. Clinical factors affecting outcome of patients BTTwith VAD
PedsQL section
Ventilator use on day
before VAD implantation
Hemodialysis use on day before
VAD implantation
TPN use on day
before VAD implantation Pump change Race
Parent
education level
Yes
(n ¼ 12)
No
(n ¼ 9)
P
value
Yes
(n ¼ 2)
No
(n ¼ 19)
P
value
Yes
(n ¼ 12) No (n ¼ 9)
P
value
Yes
(n ¼ 10) No (n ¼ 3)
P
value
Black
(n ¼ 7)
Hispanic
(n ¼ 10)
White
(n ¼ 4)
P
value
HS incomplete
or less (n ¼ 4)
HS complete
(n ¼ 5)
Some college or
more (n ¼ 12)
Core
Psychosocial 84.8 (66.7-92) 78.3 (70-81.7) .28 82.7 (65.4-100) 81.7 (70-87.5) .69 84.8 (74.2-92) 73.3 (63.5-81.7) .08 84.8 (63.5-98.3) 78.3 (71.9-85.3) .81 73.3 (70-80) 83.3 (63.5-85) 94.2 (77.7-99.2) .22 82.3 (71.7-84.8) 70 (61.7-83.3) 82.5 (71.7-95.3)
Physical 90.6 (76.6-98.4) 87.5 (71.9-93.7) .70 81.2 (62.5-100) 90.6 (75-95.3) 1.00 92.2 (68.7-100) 87.5 (75-93.7) .55 84.4 (50-100) 93.7 (78.1-96.9) .69 96.9 (82.8-100) 76.6 (67.9-85.9) 92.2 (78.9-96.6) .21 76.6 (62.5-85.9) 71.9 (34.4-90.6) 93.7 (82.8-100)
Total 83.9 (69.7-93.5) 80.4 (70.6-85.9) .51 82.1 (64.3-100) 81.94 (71.04-90.4) .86 83.9 (75.9-93.5) 78.3 (68-85.6) .34 85 (67.9-96.4) 85.9 (75.1-89.4) .81 80.4 (74.5-87) 81.2 (67.9-85.9) 94.9 (78.9-96) .36 76.7 (69.6-83.4) 70.6 (51.2-85.9) 87 (79.3-94.5)
Cardiac
Heart problems
and treatment
91.1 (85.4-100) 92.9 (85.7-96.4) .81 98.2 (96.4-100) 89.3 (85.7-98.2) .24 92.9 (85.7-100) 89.3 (85.7-96.4) .75 92.9 (89.8-100) 96.4 (91.1-98.2) .81 85.7 (82.1-98.2) 91.1 (85.7-100) 94.6 (91.1-98.2) .61 91.1 (87.1-92.9) 100 (85.7-100) 91.1 (85.7-98.2)
Treatment II 95.8 (81.7-100) 100 (83.3-100) .86 91.7 (83.3-100) 100 (81.7-100) 1.00 95.8 (83.3-100) 100 (80-100) .86 100 (91.7-100) 83.3 (79.2-91.7) .37 100 (85-100) 95.8 (75-100) 91.7 (83.3-100) .91 87.5 (70.8-100) 100 (91.7-100) 95 (83.3-100)
Perceived physical
appearance
100 (87.5-100) 100 (83.3-100) .81 100 (100-100) 100 (83.3-100) .47 100 (95.8-100) 100 (83.3-100) .34 100 (91.7-100) 100 (83.3-100) .81 100 (91.7-100) 100 (83.3-100) 100 (91.7-100) .85 95.8 (68.7-90.6) 100 (100-100) 100 (83.3-100)
Treatment anxiety 100 (68.7-100) 87.5 (56.2-100) .55 50 (0-100) 87.5 (68.7-100) .69 81.2 (40.6-100) 100 (81.2-100) .34 93.75 (75-100) 0.00 (0-43.7) .08 100 (87.5-100) 78.1 (50-100) 87.5 (37.5-100) .48 78.1 (68.7-90.6) 100 (56.2-100) 93.7 (62.5-100)
Cognitive problems 71.67 (39.2-100) 80 (50-85) 1.00 75 (50-100) 80 (47.5-93.3) .61 55 (42.5-95.8) 83.33 (50-95) .46 70 (50-91.7) 40 (36.7-45) .08 50 (42.5-97.5) 81.7 (50-100) 70 (55-85.8) .94 84.2 (66.7-92.5) 100 (50-100) 55 (42.5-85.8)
Communication 95.83 (66.7-100) 100 (33.3-100) .86 50 (0-100) 100 (66.7-100) .61 91.7 (45.8-100) 100 (91.7-100) .51 75 (25-100) 100 (50-100) .81 100 (79.2-100) 100 (25-100) 91.7 (41.7-100) .89 62.5 (12.5-100) 100 (66.7-100) 100 (75-100)
Data reported as median and interquartile range (25th-75th percentile). BTT, Bridge to transplantation; VAD, ventricular assist device; PedsQL, Pediatric Quality of Life Inventory; TPN, total parenteral nutrition;HS, high school;CPB,
cardiopulmonary bypass; SES, socioeconomic status; CC, correlation coefficient.
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Parent
education level
Heart failure
etiology Previous CPB SES Age at follow-up
Interval since
transplantation Ischemic time
Reoperation
frequency on VAD
VAD-related
infection
Pump change
frequency
P value
Acquired
(n ¼ 18)
Congenital
(n ¼ 3)
P
value
No
(n ¼ 17)
Yes
(n ¼ 4)
P
value CC P value CC P value CC P value CC P value CC P value CC P value CC P value
.47 70 (70-91.7) 83.3 (65-75.8) .15 80 (70-90) 83.1 (70.8-88.5) 1.00 0.19 .41 0.03 .89 0.40 .07 0.12 .64 0.27 .24 0.18 .44 0.29 .33
.08 78.1 (75-96.9) 90.6 (75-89.1) 1.00 90.6 (75-96.9) 85.9 (64.1-96.9) 1.00 0.13 .58 0.39 .08 0.38 .87 0.28 .25 0.09 .69 0.14 .54 0.01 .98
.20 70.6 (71.4-93.5) 83.4 (69.3-79.3) .53 81.9 (70.6-93.5) 79.7 (69.7-90.4) .96 0.19 .40 0.18 .43 0.41 .07 0.1 .69 0.24 .29 0.2 .38 0.25 .40
.73 85.7 (85.71-69.35) 92.9 (82.1-91.1) .41 92.9 (85.7-100) 89.3 (82.1-94.6) .52 0.13 .58 0.16 .49 0.03 .89 0.05 .84 0.05 .82 0.25 .27 0.02 .94
.64 90 (83.3-100) 100 (85-95) .74 100 (83.3-100) 95 (82.5-100) .96 0.06 .78 0.09 .69 0.25 .27 0.3 .21 0.08 .74 0.09 .68 0.17 .57
.66 100 (91.7-1000) 100 (83.3-100) .96 100 (91.7-100) 91.7 (75-100) .57 0.04 .85 0.21 .35 0.23 .31 0.06 .82 0.09 .68 0.29 .19 0.22 .46
.89 87.5 (62.5-100) 93.75 (71.8-93.7) 1.00 87.5 (62.5-100) 93.7 (43.7-100) 1.00 0.11 .65 0.25 .28 0.06 .81 0.24 .33 0.05 .83 0.03 .89 0.31 .31
.36 50 (50-95) 80 (40-75) .67 80 (50-95) 41.7 (31.7-41.7) .27 0.004 .99 0.26 .25 0.02 .92 0.02 .93 0.08 .74 0.002 .99 0.49 .09
.77 91.7 (62.5-95.8) 100 (66.7-100) .74 100 (66.7-100) 62.5 (16.7-95.8) .27 0.13 .56 0.55 .01 0.52 .01 0.06 .81 0.03 .9 0.16 .50 0.11 .71
APPENDIX TABLE 2. Continued
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